Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Gloria, Esteso"'
Autor:
María-José Felgueres, Gloria Esteso, Álvaro F. García-Jiménez, Ana Dopazo, Nacho Aguiló, Carmen Mestre-Durán, Luis Martínez-Piñeiro, Antonio Pérez-Martínez, Hugh T. Reyburn, Mar Valés-Gómez
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-16 (2024)
Abstract The short-lived nature and heterogeneity of Natural Killer (NK) cells limit the development of NK cell-based therapies, despite their proven safety and efficacy against cancer. Here, we describe the biological basis, detailed phenotype and f
Externí odkaz:
https://doaj.org/article/bd24417e2d61481aba2a499fb276ab1b
Autor:
Eduardo Moreo, Aitor Jarit-Cabanillas, Iñaki Robles-Vera, Santiago Uranga, Claudia Guerrero, Ana Belén Gómez, Pablo Mata-Martínez, Luna Minute, Miguel Araujo-Voces, María José Felgueres, Gloria Esteso, Iratxe Uranga-Murillo, Maykel Arias, Julián Pardo, Carlos Martín, Mar Valés-Gómez, Carlos del Fresno, David Sancho, Nacho Aguiló
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-17 (2023)
Abstract Intravesical administration of Bacillus Calmette-Guérin (BCG) was one of the first FDA-approved immunotherapies and remains a standard treatment for bladder cancer. Previous studies have demonstrated that intravenous (IV) administration of
Externí odkaz:
https://doaj.org/article/cddf6509eb5149ae82e3ae71ebde6322
Autor:
Gloria Esteso, María José Felgueres, Álvaro F. García-Jiménez, Christina Reyburn-Valés, Alberto Benguría, Enrique Vázquez, Hugh T. Reyburn, Nacho Aguiló, Carlos Martín, Eugenia Puentes, Ingrid Murillo, Esteban Rodríguez, Mar Valés-Gómez
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTBacillus Calmette-Guérin (BCG), the nonpathogenic Mycobacterium bovis strain used as tuberculosis vaccine, has been successfully used as treatment for non-muscle invasive bladder cancer for decades, and suggested to potentiate cellular and h
Externí odkaz:
https://doaj.org/article/d8013a98d0e348c39add8c2094c07125
Autor:
Marta Ibáñez-Navarro, Adrián Fernández, Adela Escudero, Gloria Esteso, Carmen Campos-Silva, Miguel Ángel Navarro-Aguadero, Alejandra Leivas, Beatriz Ruz Caracuel, Carlos Rodríguez-Antolín, Alejandra Ortiz, Alfonso Navarro-Zapata, Carmen Mestre-Durán, Manuel Izquierdo, María Balaguer-Pérez, Cristina Ferreras, Joaquín Martínez-López, Mar Valés-Gómez, Antonio Pérez-Martínez, Lucía Fernández
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionRefractory/relapsed pediatric acute leukemia are still clinically challenging and new therapeutic strategies are needed. Interactions between Natural Killer Group 2D (NKG2D) receptor, expressed in cytotoxic immune cells, and its ligands (
Externí odkaz:
https://doaj.org/article/a050597990ec4b1fb78353f27eb60db9
Autor:
Eva Castellano, Célia Samba, Gloria Esteso, Laura Simpson, Elena Vendrame, Eva M. García‐Cuesta, Sheila López‐Cobo, Mario Álvarez-Maestro, Ana Linares, Asier Leibar, Thanmayi Ranganath, Hugh T. Reyburn, Luis Martínez‐Piñeiro, Catherine Blish, Mar Valés‐Gómez
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
High grade non-muscle-invasive bladder tumours are treated with transurethral resection followed by recurrent intravesical instillations of Bacillus Calmette Guérin (BCG). Although most bladder cancer patients respond well to BCG, there is no clinic
Externí odkaz:
https://doaj.org/article/86d96bbb33ea4821b94baed32ef23626
Autor:
Gloria Esteso, Nacho Aguiló, Esther Julián, Omodele Ashiru, Mei. M. Ho, Carlos Martín, Mar Valés-Gómez
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Natural Killer cell receptors allow this heterogeneous immune population to efficiently fight both tumors and infection, so their use as immunotherapy agents is an active field of research. Cytokine activation, particularly by myeloid cell-derived IL
Externí odkaz:
https://doaj.org/article/be1ae3a0c3704bdf810a75ce97369ceb
Autor:
Carmen Campos-Silva, Silvia López-Borrego, María José Felgueres, Gloria Esteso, Mar Vales-Gomez
Publikováno v:
Critical Reviews in Immunology. 42:21-40
The identification of biomarkers allowing diagnostics, prognostics and patient classification is still a challenge in oncological research for patient management. Improvements in patient survival achieved with immunotherapies substantiate that biomar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97a7544924b5c7a884292aef554a5089
https://doi.org/10.1615/critrevimmunol.2022045263
https://doi.org/10.1615/critrevimmunol.2022045263
Autor:
Gloria Esteso, María José Felgueres, Álvaro F. García-Jiménez, Christina Reyburn-Valés, Alberto Benguría, Enrique Vázquez, Hugh T. Reyburn, Nacho Aguiló, Carlos Martín, Eugenia Puentes, Ingrid Murillo, Esteban Rodríguez, Mar Valés-Gómez
Publikováno v:
Oncoimmunology. 12(1)
Bacillus Calmette-Guérin (BCG), the nonpathogenic Mycobacterium bovis strain used as tuberculosis vaccine, has been successfully used as treatment for non-muscle invasive bladder cancer for decades, and suggested to potentiate cellular and humoral i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a9347c310a9c290a50ae736a4d4dc0f
https://pubmed.ncbi.nlm.nih.gov/36567803
https://pubmed.ncbi.nlm.nih.gov/36567803
Autor:
Eva M. García-Cuesta, Gloria Esteso, Omodele Ashiru, Sheila López-Cobo, Mario Álvarez-Maestro, Ana Linares, Mei M. Ho, Luis Martínez-Piñeiro, Hugh T. Reyburn, Mar Valés-Gómez
Publikováno v:
OncoImmunology, Vol 6, Iss 4 (2017)
Immunotherapy, via intra-vesical instillations of BCG, is the therapy of choice for patients with high-risk non-muscle invasive bladder cancer. The subsequent recruitment of lymphocytes and myeloid cells, as well as the release of cytokines and chemo
Externí odkaz:
https://doaj.org/article/308ab036fc69419b8acbc58d2f4089a7
Autor:
NACHO AGUILO, Eduardo Moreo, Iñaqui Robles, Claudia Guerrero, Aitor Jarit, María José Felgueres, Gloria Esteso, Iratxe Uranga-Murillo, Santiago Uranga, Ana Belen Gomez, Julian Pardo, Carlos Martin, Mar Vales-Gomez, Carlos del Fresno, David Sancho
Intravesical administration of BCG was the first immunotherapy approved by the FDA and it is still nowadays the treatment of choice for a subset of non-muscle invasive bladder cancer patients. Considering this precedent and the strong capabilities of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac5c6f628eae5b6ab8e8341a7e19228b
https://doi.org/10.21203/rs.3.rs-2086495/v1
https://doi.org/10.21203/rs.3.rs-2086495/v1
